To check the drug sensitivity of NSCLC cells upon MIR31HG genetic manipulation, we tested the IC50 of two EGFR-targeting inhibitors (gefitinib and osimertinib) and two conventional chemotherapy drugs (DDP and GEM). Here, EGFR is linked to non-small cell lung carcinoma.